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Abstract
Background: The genome of human cytomegalovirus (HCMV) has been studied extensively, particularly in the
UL/b’ region. In this study, transcripts of one of the UL/b’ genes, UL144, were identified in 3 HCMV isolates
obtained from urine samples of congenitally infected infants.
Methods: Northern blot hybridization, cDNA library screening, and RACE-PCR were used.
Results: We identified at least 4 differentially regulated 3’-coterminal transcripts of UL144 in infected cells of 1,300,
1,600, 1,700, and 3,500 nucleotides (nt). The 1600 nt transcript was the major form of UL144 mRNA. The largest
transcript initiated from the region within the UL141 open reading frame (ORF) and included UL141, UL142, UL143,
UL144, and UL145 ORFs.
Conclusions: These findings reveal the complex nature of the transcription of the UL144 gene in clinical isolates.
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Background
Cytomegaloviruses (CMVs) are members of the subfam-
ily Betaherpesvirinae of the family Herpesviridae.
Human cytomegalovirus (HCMV) is a common cause of
congenital viral infections and a frequent opportunistic
pathogen in transplant recipients and AIDS patients
[1-3]. The relative genomic complexity of HCMV is mir-
rored by its biological characteristics, as the most rele-
vant cellular reservoirs of the latent virus and its sites
for permissive replication have not been conclusively
established and its pathogenesis is not well understood.
Like other CMVs, HCMV has a very specific host range,
but within a permissive host it enters and replicates in a
wide variety of cell types [3,4].
The HCMV genome consists of 230 to 235 kb of dou-
ble stranded DNA and more than 160 predicted open
reading frames (ORFs) [5-8]. The overall nucleotide
sequence of strains isolated from unrelated sources is
relatively conserved. However, the sequences of specific
ORFs can be highly variable, including RL6, RL12, UL4,
U L 1 8 ,U L 5 5( g B ) ,U L 7 3( g N ) ,U L 7 4( g O ) ,U L 1 3 9 ,
UL144, and UL146 [5,9-18].
The HCMV UL144 ORF encodes a homologue of the
herpesvirus entry mediator (HVEM) [19], which is a
member of the tumor necrosis factor receptor (TNFR)
superfamily and contributes to the ability of HCMV to
escape immune clearance. Although the UL144 gene has
been well characterized at the DNA and protein levels,
no detailed analysis of its mRNA transcripts has been
reported. In the current study, we characterized the
transcripts of the UL144 gene in 3 clinical strains.
Methods
Cells and virus
Human embryonic lung fibroblast (HELF) cells were
g r o w ni nD u l b e c c o ’s modified Eagle’s medium supple-
mented with 10% (vol/vol) fetal calf serum. Three
HCMV clinical isolates, named H, Xu, and Ch, were
categorized as Group C, A, and B, according to the
schema of Lurain et al [9]. The isolates were derived
from urine samples of three congenitally HCMV-
infected children in the Pediatrics Department at the
Affiliated Shengjing Hospital of China Medical Univer-
sity. All samples were collected with the permission of
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approval of the Hospital Ethical Committee. HELF cells
were infected with the virus at a multiplicity of infection
of approximately 10 plaque-forming units (PFU) per
cell. Virus DNA of HCMV isolate H was extracted as
previously described [20] and its UL/b’ region was
sequenced using a previously described shotgun sequen-
cing method [21].
RNA preparation
Total RNA was extracted from uninfected and HCMV-
infected HELF cells using a standard guanidium isothyo-
cyanate and phenol:chloroform method [22]. The
extracts were treated with DNase I (Ambion, USA).
Immediate early (IE) RNA was prepared in the presence
of 100 μg/mL cycloheximide (Sigma, USA) at 24 hours
post-infection (hpi), early (E) RNA was extracted in the
presence of 100 μg/mL phosphonoacetic acid (Sigma) at
48 hpi, late RNA was extracted in the absence of block-
ing agents at 96 hpi, and control RNA was extracted
from uninfected cells [23].
Screening of the cDNA library
A cDNA library of the HCMV clinical strain H had
been previously constructed using the pBluescript II SK
vector [24]. The primary library consisted of 1.12 × 10
6
recombinant clones/mL. Nearly 95% of the vectors con-
tained inserts, as determined by blue-white plaque
screening on NZY agar plates containing 5-bromo-4-
chloro-3-indolyl-b-D-galactopyranoside (X-Gal) and iso-
propyl-b-D-thio-galactoside (IPTG). The average length
of the inserts was 1.2 kb as determined by PCR with
M13 primers and the Gel Image System.
A total of 4,000 single clones were randomly picked
and inoculated in LB medium. In order to identify gene-
specific clones, aliquots of the 4,000 cultures were
m i x e ds t e pb ys t e pa sf o l l o w s :am i x t u r eo fe v e r y1 0
individual clones was designated as the first grade of
colonies, a mixture of every 10 of the first grade of colo-
nies as the second grade of colonies, and a mixture of
every 10 of the second grade of colonies as the third
grade of colonies, equivalent to 1000 clones. Each grade
of the colonies was inoculated into fresh medium. Cells
were lysed using a cell lysis buffer (50 mM Tris-HCl,
pH 6.8, 15 mM NaCl, 5 mM EDTA, 0.5% NP-40). The
UL144-containing cDNA clones were identified by PCR
using a set of primers, 144For2 and 144Rev1 (Table 1),
covering the whole UL144 ORF, and each of the DNA
preparations from the third, second, and first grade of
colonies and single clones were used as templates,
sequentially. The PCR conditions were an initial dena-
turation step at 94°C for 5 min, 30 cycles of 94°C for 30
sec, 50°C for 30 sec, and 72°C for 1 min, followed by a
final elongation step at 72°C for 5 min. Identified clones
were sequenced using the T7 primer of the pBluescript
II SK vector with an ABI PRISM 3730 DNA analyzer.
Only sequences with additional polyadenylated residues
at their 3’ terminal ends were included as entire mRNA
sequences.
A complete list of all primers is provided in Table 1.
Northern blot hybridization
RNA was prepared from uninfected cells and cells
infected with HCMV clinical isolates H, Ch, and Xu at
IE, E, and L phases. RNA was analyzed by Northern
blot to identify the transcripts of UL144.
Five micrograms of RNA was size-fractionated in a
1.2% denaturing agarose ge la n dt r a n s f e r r e dt oam e m -
brane (N-Hybond, Amersham Biosciences) by capillary
blotting. A UL144 gene-specific probe was labeled with
digoxigenin-dUTP, hybridized to the membrane, and
detected by its NBT/BCIP chromogenic signal according
to the manufacturer’s instructions (DIG Northern starter
kit, Roche Diagnostics, Mannheim, Germany). RNA
representing the noncoding strand was generated using
T7 RNA polymerase and labeled by incorporation of
digoxigenin-dUTP. Three probes were produced accord-
ing to the different sequences of isolates H, Ch, and Xu
using the primers 144For2 and 144Prob (Table 1). The
labeled probes were antisense to the 531 bp of the com-
plete UL144 protein coding sequences (nucleotides
11584-12114, GQ981646 as reference) of the three iso-
lates. Hybridization to the RNA blots was carried out at
55°C overnight. The blots were visualized by the addi-
tion of an anti-digoxigenin antibody labeled with alka-
line phosphatase followed by the addition of the
Table 1 Primers used for PCR amplification, Northern-blot and selection of cDNA clones.
Name of Primers Sequence Position in UL144 ORF Position in GQ981646
144Rev1 5’-ttacagggtgcggtagaaaatt-3 510-531 12093-12114
144Rev2 5’-acaaccaggctagagtatgacgacc-3’ 388-412 11971-11995
144For1 5’-gtgaagatggctgactatcct-3’ -182~-162 11401-11421
144For2 5’-atgaagcctctggtgatgct-3’ 1-20 11584-11603
144For3 5’-aaaatgtgtaagcccgatga-3’ 61-80 11644-11663
144Prob 5’-taatacgactcactatagggttacagggtgcggtagaaaattttg-3’ 507-531 12090-12114
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(BCIP) and nitroblue tetrazolium (NBT). DIG-labeled
RNA Molecular Weight Marker I 0.31-6.95 kb (Roche
Diagnostics) was used to estimate the size of the bands
by the logarithmic relationship between molecular
weight and distance migrated.
5’ RACE To define the 5’ ends of transcripts in the
UL144 intergenic region, RNA preparations of the iso-
lates H, Ch, and Xu were analyzed by 5’ RACE, which
was carried out with the 5’-Full RACE kit (Takara,
Japan) according to the manufacturer’si n s t r u c t i o n s .
Briefly, the RNA preparation was treated with calf intes-
tine alkaline phosphatase (CIAP, 4.8 U/μgR N A )f o r1h
at 50°C. Then the purified RNA was treated with
tobacco acid pyrophosphorylase (TAP, 0.25 U/μgR N A )
for 1 h at 37°C. The CIAP/TAP-treated RNA was ligated
to the supplied 5’ RACE adaptor (1 μLo f1 5μM adap-
tor/2 μgR N A )w i t hb a c t e r i o p h a g eT 4R N Al i g a s e( 2 0
U/μg RNA) for 1 h at 16°C. Reverse transcription was
carried out at 42°C for 1 h with 5 U M-MLV reverse
transcriptase and 5 μM of random 9-mer primers. Con-
trol reactions were carried out in parallel using RNA
treated without M-MLV [M-MLV(-)]or TAP [TAP(-)].
All reactions were performed in the presence of 10 U
RNase Inhibitor. cDNA was amplified by nested PCR
using 1.25 U LA Taq DNA polymerase (Takara) in a 50
μL reaction mixture including LA PCR buffer (50 mM
KCl, 10 mM Tris-HCl, pH 8.3), 1.5 mM MgCl2, and 2.5
mM of each of the four deoxynucleoside triphosphates.
The primers used in the primary PCR reaction were the
5’ RACE outer primer and 144Rev1 (see Table 1 for pri-
mer coordinates within the H isolate sequence) and
those in the second PCR reaction were the 5’ RACE
inner primer and 144Rev2. The PCR conditions
included an initial denaturation step at 94°C for 3 min,
20-25 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°
C for 3 min, followed by a final extension step at 72°C
for 10 min.
3’ RACE 3’ RACE was carried out with the 3’-Full
RACE Core Set Ver. 2.0 (Takara) following the manu-
facturer’s instructions. Briefly, 500 ng of RNA was used
a sat e m p l a t et os y n t h e s i z ec D N Aw i t hA M VR e v e r s e
transcriptase for 30 min at 50°C, 5 min at 99°C and 5
min at 5°C. The external reverse primer oligo dT-adap-
tor primer with a poly (T) tract was used to prime
cDNA synthesis. cDNA of the 3 clinical isolates, includ-
ing isolates H, Ch, and Xu, was then amplified by nested
PCR with an adaptor primer and the external forward
primer 144For2 and the inner forward primer 144For3.
RT-PCR RT-PCR was carried out using the RNA PCR
Kit (AMV) Ver. 3.0 (Takara) according to the manufac-
turer’s instructions. Reverse transcription was performed
at 42°C for 1 h with 200 U of AMV Reverse Transcrip-
tase (Takara) and 25 mM of oligo dT-adaptor primer.
PCR was conducted using 10 μL of the synthesized
cDNA and primers 144For1 and 144Rev2 (Table 1) with
Ex Taq DNA polymerase. The PCR conditions for all
the amplification reactions included an initial incubation
at 94°C for 3 min, followed by 40 cycles of denaturation
at 94°C for 40 sec, annealing at 50°C for 40 sec, and
extension at 72°C for 2 min, with a final incubation at
72°C for10 min. Control reactions using RNA treated
without AMV [AMV (-)] and water as templates were
included in each set of PCR amplifications.
Cloning and sequencing
RACE and RT-PCR products were separated by electro-
phoresis on a 2% agarose gel and visualized with ethi-
dium bromide. Bands were gel purified and the
recovered fragments were ligated into a TA cloning vec-
tor, pCR (Invitrogen, USA). Inserts were sequenced by
the dideoxynucleotide method with Sequenase (Invitro-
gen) and M13For and M13Rev primers using an Applied
Biosystems automated sequencer.
Results
Identification of UL144 transcripts by cDNA library
screening
Twenty-two distinct clones were identified from the
cDNA library and all were sequenced successfully. The
3’ ends of the sequences occurred within a 3-nucleotide
(nt) window extending from nt 12,844-12,846
(GQ981646 as reference). Five groups of UL144 tran-
scripts were derived from the 22 cDNA sequences
according to their different 5’ ends. Among the 22
cDNA sequences, 15 (named as C1) transcripts were
1565-1612 nt in length with 5’ ends at nt 11,276-11,278
(GQ981646 as reference) and different lengths of poly A
tails, 4 (named as C3) were 1317 nt with their 5’ ends at
nt 11,528, and 1 (named as C2) was 1775 nt with its 5’
end at nt 11,091. The other two transcripts were 1230
nt and 1161 nt in length (named as C4 and C5, respec-
tively) and started at nt 11,635 and 11,704, respectively,
indicating that both of the transcripts initiate within the
UL144 ORF.
Mapping the 5’ end of UL144 transcript using 5’ RACE-
PCR
Eight products of approximately 100, 150, 200, 350, 465,
720, 860, and 2693 bp were obtained from the 5’ RACE-
PCR (Figure 1A). Sequencing of the products revealed
that they had different 5’ ends. The 5’ end of the 2500
bp product occurred at nt 9,303, which is located within
the UL141 ORF. This product was obtained in two sepa-
rate experiments using RNA preparations of isolate H,
but was not found in the RNA of the other two isolates.
The 5’ ends of the sequences of the 900, 700, and 500
bp products were at nt 11,100, 11,276, and 11,528,
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the RNA of all three isolates. The 5’ ends of the
sequences of the four products 350 bp in size and smal-
ler were at nt 11,637, 11,822, 11,878 and 11,935
respectively.
Mapping the 3’ end of UL144 transcript using 3’ RACE-
PCR
As shown in Figure 1B, 3’ RACE-PCR yielded two pro-
ducts of 1.3 kb and 500 bp in length. Five UL144-speci-
fic clones with the 1.3 kb band from isolates H (1), Ch
(1), and Xu (3) were sequenced. All the sequences ter-
minated at nt 12,845, except for one from isolate Xu,
which terminated at nt 12,844. Sequencing of the 500
bp band revealed it to be a nonspecific product.
Identification of UL144 transcripts by Northern blot
Northern blot revealed the hybridization of the probe
to 4 bands in RNA preparations from the L phase of
viral replication in isolate H (Figure 2). The major
band was approximately 1600 nt and it appeared
repeatedly. The three fainter bands were approximately
1300, 3000, and 3500 nt. Similar results were obtained
for isolate Ch. The four bands in RNA preparations
from the L phase of viral replication in isolate Xu were
approximately 1300, 1600, 2000, and 3500 nt. The
RNA from uninfected cells was negative in all the
hybridization experiments. No bands were found in the
RNA preparations of the IE or E phases from any of
the three strains.
Discussion
The UL144 gene is located in the UL/b’ region of the
HCMV genome, which contains approximately 20 kb of
DNA encoding at least 19 ORFs but is dispensable for
growth in vitro [25]. The UL144 ORF encodes a struc-
tural homologue of the herpesvirus entry mediator
(HVEM) [9,26], a member of the TNFR superfamily, but
it does not bind any known TNF-related ligands
[9,26,27]. It negatively regulates Th1 cells by binding to
the B- and T-cell lymphocyte activator BTLA [28],
mimicking the inhibitory co-signaling function of
HVEM. Like LMP-1 of the Epstein-Barr virus, UL144
activates TNFR-activated factor 6 (TRAF6), leading to
NF-B (nuclear factor kappa-light-chain-enhancer of
activated B cells) activation in early infection [27]. It
induces expression of the macrophage-derived chemo-
kine (MDC) [27,29,30], also termed CCL22 [chemokine
(C-C motif) ligand 22], which attracts Th2 and regula-
tory T cells. Taken together, it is possible that upregula-
tion of CCL22 by the UL144 protein may help HCMV
evade immune surveillance, resulting in increased viral
spread and dissemination. There is significant strain-
specific sequence variability in the UL144 ORF
[9,18,26,31,32] and these UL144 genotypes are asso-
ciated with congenital infection outcome [31,33]. How-
ever, no data has been reported thus far on the UL144
mRNA structure.
In this study, we provide evidence for the existence of
at least 4 differentially regulated UL144 transcripts of
1,300, 1,600, 1,700, and 3,500 nt (Table 2, Figure 3).
The 5’ ends of the 1,300, 1,600, and 1,700 nt transcripts
are within the region between the UL143 and UL144
ORFs and the transcripts all contain the same 2 ORFs
A B
Figure 1 Characterizations of the HCMV UL144 transcripts by
5’-RACE-PCR and 3’-RACE-PCR analyses.5 ’-RACE-PCR and 3’-
RACE-PCR were performed on first-strand cDNA prepared from total
RNA from HELF cells infected with HCMV for 96 h. Strains Xu, Ch, H
were analyzed respectively. A 5’-RACE-PCR analysis was performed
using the gene specific primers of 144Rev1 and 144Rev2 and the
templates prepared with (lanes3, 6 and 9) or without reverse
transcriptase (lane1, 4 and 7) during the first strand cDNA synthesis
or without tobacco acid pyrophosphorylase (lane2, 5 and 8) during
RNA treatment of the isolates. Strains Xu (lanes1-3), Ch (lanes4-6), H
(lanes7-9) were analyzed respectively. B 3’-RACE-PCR analysis was
performed on first-strand cDNA using the external forward primer
144For2 and the inner forward primer 144For3 by nested PCR
together with oligo(dt)17-adaptor. Molecular standards are labeled
‘M’. The positions of DL2000 molecular markers are indicated.
Figure 2 Northern blot analyses of UL144 transcripts.R N A
preparations from HCMV clinical strains H, Ch and Xu in
immediately early (IE), early (E) and late (L) kinetics classes were
used in this analysis. RNA from non-infected HELF cells (Z) was used
as a negative control. The Northern blot was performed with three
different probes, produced according to the sequences of the three
different isolates using 144For2 and 144Prob primers. The four
UL144 transcripts are indicated by arrows. The positions of RNA size
markers are indicated.
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be the major form since its presence was confirmed by
all of the methods used in this study, including North-
ern blot hybridization, RACE-PCR, and cDNA library
screening. At the same time, this transcript is the most
abundant based on its prevalence in the cDNA library
( 1 5o f2 2c D N Ac l o n e s )a n dt h es t r e n g t ho fi t sb a n di n
the Northern blot assay. Potential TATA and CCAAT
promoter elements at 29 and 70 bp upstream of its
initiation site, respectively, further support the existence
of this transcript. The 1,300 nt and 1,700 nt transcripts
were not as prevalent as the 1,600 nt transcript. The
1,300 nt transcript was found in 4 of 22 clones from the
cDNA library and while its genomic sequence contains
a potential TATA promoter element 13 bases upstream
of its initiation site, it does not contain a CAT box. The
transcript of 1,700 nt was present in only 1 of the 22
specific cDNA clones and was not detected by Northern
blot, most likely due to its low prevalence. It has poten-
tial TATTA and CACAT promoter elements at 50 and
90 bases upstream its initiation site, respectively. The
largest transcript, 3,500 nt in length, initiates from
within the UL141 ORF and includes UL142, UL143,
UL144, UL145, and part of UL141 ORFs. This transcript
was found by Northern blot only at long exposure times
and its initiation site was demonstrated in two separate
5’ RACE experiments using RNA preparations from iso-
late H. A potential promoter (TTACTTTTAA) and a
“CCAAAT” were found at -15 and -29 of its initiation
site, respectively. However, the presence of the 3500 nt
transcript was not confirmed in the cDNA library. The
long length of the transcript may have prevented its
ligation during the construction of the cDNA library.
In this study, all 22 UL144-specific cDNA clones ter-
minated within a 3 nt window located 100 bp down-
stream of the UL145 gene. The single poly(A) signal,
which is downstream of the UL145 stop codon, supports
the possibility of a common 3’ terminal end for these
transcripts. The 3’ terminal ends of the transcripts were
confirmed by 3’ RACE using RNA from all the three
isolates. The presence of 3’ coterminal transcripts
around the UL144 region is similar to that found in
other genomic regions of HCMV, including the UL93-
UL99 ORFs [34], UL146-UL132 ORFs [35], and M73
and M73.5 genes [36]. It is possible that their different
5’ non-coding sequences may have regulatory functions,
warranting further investigation.
We obtained some small RNA fragments in our cDNA
library and by 5’ RACE that initiates inside the UL144
ORF. These RNA fragments are most likely products
from incomplete transcription. Transcripts of approxi-
mately 3,000 nt in the RNA of isolates H and Ch and
approximately 2,000 nt in the RNA of isolate Xu were
present in our Northern blots but were not confirmed
by cDNA library screening or 5’ RACE-PCR, indicating
that they may be due to non-specific hybridization.
Conclusions
In this study, we have demonstrated that the transcripts
of UL144 have a complex transcriptional pattern of
overlapping transcripts that differ at their 5’ initiation
sites in different UL144 genotype isolates. At least 4
transcripts were identified in the 3 clinical isolates stu-
died. These findings reveal the complex nature of the
transcription of the UL144 gene in clinical isolates.
Table 2 Transcripts of the HCMV UL144 gene demonstrated in this study.
Transcripts The position of
5’ end of the
transcript
Isolates in which
transcripts were
identified
Amounts. of
cDNA clones from
the library
Strength of
reaction in
Northern blot
Position and
forms of the
TATA-box
Position and
forms of the
CAT-box
1,600 nt 11276 H,CH,XU 15 ++++ 11247-11250,TATA 11206-11210,
CCAAT
1,300 nt 11528 H,CH,XU 4 ++ 11515-11519.TATTA -
3,500 nt 9303 H 0 + 9288-9297.
TTACTTTTAA
9274-9279.
CCAAAT
1,700 nt 11091 H,CH,XU 1 - 11040-11044.
TATTA
11001-11005.
CACAT
Note: all of the transcripts share the same 3’ end at nt 12844-12846. Nucleotide numbers are based on the UL/b’ region sequence of isolate H (GenBank
accession number GQ981646).
8 , 0 0 0        9 , 0 0 0       1 0 , 0 0 0        1 1 , 0 0 0        1 2 , 0 0 0       1 3 , 0 0 0  
UL141      UL142   UL143      UL144    UL145     
Figure 3 Summary of UL144 mapping results. Transcripts of the
HCMV UL144 gene demonstrated in this study are indicated. All of
the transcripts share the same 3’ end at nt 12844-12846. Nucleotide
numbers are based on the UL/b’ region sequence of isolate H
(GenBank accession number GQ981646).
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